LAUSR

Emerging biologic therapies for hypercholesterolaemia

Sign Up to like & get
recommendations!
0 Published in 2017 at "Expert Opinion on Biological Therapy"

DOI: 10.1080/14712598.2017.1341485

Abstract: ABSTRACT Introduction: LDL-cholesterol (LDL-C) is one of the most well-established risk factors for CV disease. Indeed, therapies that decrease LDL-C are proven to effectively reduce the risk of atherosclerotic CV disease. Monoclonal antibodies (mAbs) that… read more here.

Keywords: reduction; biologic therapies; risk; pcsk9 ... See more keywords

Emerging biologic frontiers for Sjogren’s syndrome: Unveiling novel approaches with emphasis on extra glandular pathology

Sign Up to like & get
recommendations!
0 Published in 2024 at "Frontiers in Pharmacology"

DOI: 10.3389/fphar.2024.1377055

Abstract: Primary Sjögren’s Syndrome (pSS) is a complex autoimmune disorder characterized by exocrine gland dysfunction, leading to dry eyes and mouth. Despite growing interest in biologic therapies for pSS, FDA approval has proven challenging due to… read more here.

Keywords: syndrome unveiling; pathology; frontiers sjogren; emerging biologic ... See more keywords

Current and emerging biologic therapies targeting eosinophilic granulomatosis with polyangiitis

Sign Up to like & get
recommendations!
0 Published in 2024 at "Rheumatology"

DOI: 10.5114/reum/193351

Abstract: on the other hand, binds to the IL-5R α subunit on eosinophils and basophils, inducing eosinophil depletion via antibody-dependent cell-mediated cytotoxicity (ADCC), leading to a more direct and rapid reduction in eosinophil levels. One clinical… read more here.

Keywords: eosinophilic granulomatosis; biologic therapies; therapies targeting; emerging biologic ... See more keywords